| abstract |
Embodiments of the disclosure concern methods and compositions related to treatment of diabetes and/or related conditions using cell therapy. In specific embodiments, cells that lacked the ability to produce insulin are exposed to one or more particular agents that render the cells to have the ability to produce insulin, and these cells are provided to an individual in need thereof. In a specific embodiment, the agent(s) are Wnt5a, FGF7, WNT3a, HGF, THBS2, IGF1, PDPN, LIF, endocan, SERPINF1, EGF, or a combination thereof. |